News headlines about Mesa Laboratories (NASDAQ:MLAB) have trended positive recently, according to Alpha One. Alpha One, a service of Accern, rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mesa Laboratories earned a daily sentiment score of 0.31 on Alpha One’s scale. Alpha One also assigned media stories about the medical instruments supplier an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the near future.

Separately, Zacks Investment Research cut Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, April 12th.

Mesa Laboratories (NASDAQ:MLAB) traded up 1.65% during midday trading on Monday, hitting $142.63. The stock had a trading volume of 8,561 shares. The stock has a market cap of $527.73 million, a price-to-earnings ratio of 47.17 and a beta of 0.61. The stock has a 50 day moving average of $130.47 and a 200 day moving average of $125.91. Mesa Laboratories has a 12 month low of $97.96 and a 12 month high of $147.58.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Thursday, February 2nd. The medical instruments supplier reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.57. Mesa Laboratories had a net margin of 12.24% and a return on equity of 18.52%. The company had revenue of $23.84 million for the quarter, compared to analyst estimates of $22.60 million. Analysts expect that Mesa Laboratories will post $2.97 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Shareholders of record on Wednesday, May 31st will be given a dividend of $0.16 per share. The ex-dividend date is Friday, May 26th. This represents a $0.64 annualized dividend and a yield of 0.45%. Mesa Laboratories’s payout ratio is currently 21.12%.

In other Mesa Laboratories news, Director H Stuart Campbell sold 8,000 shares of the company’s stock in a transaction dated Tuesday, February 7th. The shares were sold at an average price of $121.55, for a total transaction of $972,400.00. Following the transaction, the director now directly owns 55,930 shares in the company, valued at $6,798,291.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John James Sullivan sold 5,922 shares of the company’s stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $123.99, for a total transaction of $734,268.78. Following the transaction, the chief executive officer now owns 68,040 shares in the company, valued at $8,436,279.60. The disclosure for this sale can be found here. Insiders have sold 38,070 shares of company stock worth $4,713,296 over the last 90 days. 17.00% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

5 Day Chart for NASDAQ:MLAB

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with's FREE daily email newsletter.